Related Experiment Video
Updated: May 31, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
A review of cutting-edge biomarkers for diagnosing coronary artery disease
Pouria Azami1, Sahand Mohammadzadeh2, Soroush Seirafi3
1Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Insights
New biomarkers show promise for early detection of chronic coronary artery disease (CAD). These innovative markers could improve risk stratification and patient outcomes, aiding in the reduction of CAD morbidity and mortality.
Area of Science:
- Cardiovascular Medicine
- Biomarker Discovery
- Diagnostic Innovation
Background:
- Chronic coronary artery disease (CAD) presents a significant global health challenge.
- Existing risk assessment tools lack sufficient sensitivity for early detection and precise risk stratification.
- There is a critical need for novel biomarkers to facilitate early CAD diagnosis and reduce associated mortality.
Purpose of the Study:
- To review recent advancements in emerging biomarkers for the detection of chronic CAD.
- To analyze the mechanisms, pathophysiology, and measurement techniques of these novel biomarkers.
- To comparatively assess the diagnostic performance of identified biomarkers in CAD patients versus control groups.
Main Methods:
- Comprehensive literature review of emerging biomarkers for CAD detection.
- Analysis of biomarker mechanisms, pathophysiology, and clinical measurement techniques.
- Comparative performance assessment using sensitivity, specificity, and AUC values.
Main Results:
- Tenascin-C, IL-37, PTX3, transthyretin, soluble interleukin-6 receptor α, and miR-15a demonstrate high diagnostic potential for chronic CAD.
- These biomarkers exhibit promising performance metrics in distinguishing CAD patients from controls.
- The identified biomarkers show potential for enhancing CAD risk stratification and enabling early intervention.
Conclusions:
- Novel biomarkers offer a promising avenue for improving early detection and risk stratification in chronic CAD.
- Further research, including randomized controlled trials, is necessary to validate these biomarkers for routine clinical practice.
- The development of ideal, inclusive biomarkers remains an ongoing pursuit due to the complex nature of CAD.
Abstract:
Chronic coronary artery disease (CAD) remains a significant global healthcare burden. Current risk assessment methods have notable limitations in early detection and risk stratification. Hence, there is an urgent need for innovative biomarkers that facilitate the premature CAD diagnosis, ultimately leading to reduction in associated morbidity and mortality rates. This review comprehensively examines recent advances in emerging biomarkers for CAD detection. Our analysis delves into various aspects of these biomarkers such as their mechanisms of action, roles in the pathophysiology of the disease, and different measurement techniques employed in clinical practice. Comparative assessment of biomarker performance between CAD patients and control groups was also presented relying on their sensitivity, specificity, and area under the curve at specific cutoff points. In this regard, prominent biomarkers including Tenascin-C, IL-37, PTX3, transthyretin, soluble interleukin-6 receptor α, and miR-15a are identified as having high diagnostic potential for chronic CAD that indeed showcase promising performance metrics. These findings underscore the role of novel biomarkers in enhancing CAD risk stratification and improving patient outcomes through early intervention. However, the pursuit of an ideal and inclusive biomarker continues due to the multifaceted nature of CAD. Future randomized controlled trials are essential to bridge the gap between research findings and clinical practice in order to augment the practical application of these biomarkers in routine healthcare settings.
More Related Videos
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...